CareDx, Inc.

CareDx reported a substantial turnaround in its financial performance for the second quarter of 2026, achieving a net income of $110.6 million, or $2.07 diluted EPS, compared to a net loss in the prior year. This significant improvement was primarily driven by a $113.0 million gain from the sale of its lab products business. The company also saw a 52.2% increase in total revenue to $131.9 million and a substantial boost in cash and cash equivalents.

CareDx, Inc. reported strong second-quarter 2026 financial results, with revenue increasing 52% year-over-year to $132 million and GAAP net income reaching $111 million. The company also significantly raised its full-year 2026 revenue guidance to $490 million-$500 million and Adjusted EBITDA guidance to $66 million-$78 million. These results follow the divestiture of its Lab Products business, which generated a $113 million gain, and the acquisition of Naveris, strengthening its focus on precision medicine diagnostics.

CareDx, Inc. completed the acquisition of Naveris, Inc. for $161.8 million in cash, with potential additional payments of up to $100 million based on revenue milestones. This strategic move expands CareDx's leadership into high-growth specialty oncology, increasing its estimated addressable market to over $12 billion. Concurrently, CareDx divested its Lab Products business to Eurobio Scientific for $171.7 million in cash, aiming to sharpen its focus on U.S. precision medicine testing services and patient and digital solutions.

CareDx, Inc. held its 2026 Annual Meeting of Stockholders where shareholders approved an amendment to the 2024 Equity Incentive Plan, increasing the shares reserved by 1,600,000. Stockholders also elected five directors, ratified Deloitte & Touche LLP as the independent auditor for 2026, and approved executive compensation on an advisory basis. They also advised a one-year frequency for future advisory votes on executive compensation.

CareDx, Inc. reported a significant improvement in its first quarter 2026 financial results, achieving net income of $2.8 million, a substantial turnaround from a net loss of $10.4 million in Q1 2025. Total revenue increased by 39% to $117.7 million, driven primarily by strong growth in testing services and patient and digital solutions. The company also saw a positive shift in operating cash flow, providing $4.3 million compared to using $26.6 million in the prior year.

CareDx announced a definitive agreement to acquire Naveris, a precision oncology diagnostics company, for an upfront cash consideration of $160 million, with up to an additional $100 million based on revenue milestones. This strategic acquisition extends CareDx's precision medicine testing services into specialty oncology, targeting a $4.5 billion market. Concurrently, CareDx reported strong first-quarter 2026 financial results, with revenue increasing 39% year-over-year to $118 million and GAAP net income reaching $3 million. The company also raised its full-year 2026 revenue guidance to $447-$465 million and Adjusted EBITDA guidance to $43-$57 million, and announced the divestment of its Lab Products business for $170 million.

CareDx, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 11, 2026. Stockholders will vote on the election of five directors, the ratification of Deloitte & Touche LLP as the independent auditor, advisory votes on executive compensation and its frequency, and an amendment to the 2024 Equity Incentive Plan to increase reserved shares. The Board size will decrease from ten to eight members, with Dr. Peter Maag and Arthur A. Torres not standing for re-election.

CareDx, Inc. announced compensation adjustments for Keith Kennedy, who was appointed Chief Financial Officer and Chief Operating Officer. In recognition of his expanded responsibilities, the Compensation and Human Capital Committee approved an award of 24,134 restricted stock units (RSUs) and 24,134 performance-based restricted stock units (PRSUs). The RSUs will vest over time, starting April 6, 2027, while the PRSUs are subject to performance achievement over 2026 and 2027.

CareDx, Inc. has entered into a Purchase Agreement with Eurobio Scientific S.A. to divest its kitted laboratory products business and related software. The transaction, valued at $170 million in cash, includes the sale of CareDx AB, a wholly-owned Swedish subsidiary. The deal is subject to customary closing conditions, including regulatory approval, and is expected to close by October 15, 2026.